Bayer Lands Merck Consumer As Springboard to Lead Global OTC Industry
This article was originally published in The Tan Sheet
Executive Summary
The $14.2 billion deal is “a major milestone on our path toward global leadership” in OTC sales, says Bayer Chairman Marijn Dekkers. The acquisition focuses on expanding international sales of Merck products including the Claritin allergy, Coppertone sunscreen and MiraLax constipation lines.